Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Advanced Grade 3 Neuroendocrine Carcinomas
NCT03278405Phase 2Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in neuroendocrine carcinoma (NEC), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Overall Response Rate at 2 years. Started Nov 2017; status: completed.
02
Drugs
avelumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03278405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278405.